Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients
- 1 July 2003
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Nephrology and Hypertension
- Vol. 12 (4), 373-379
- https://doi.org/10.1097/00041552-200307000-00005
Abstract
Hyperphosphatemia in patients with end-stage renal disease leads to secondary hyperparathyroidism and renal osteodystrophy, and is independently associated with mortality risk. How hyperphosphatemia increases mortality risk is unknown but it may promote cardiovascular calcification. It is recommended that dialysis patients be treated to maintain normal serum phosphorus. Although calcium-based phosphate binders are cost-effective, their long-term safety has been questioned because of their postulated role in progression of cardiovascular calcification. In this regard, sevelamer hydrochloride has been recommended as an alternative phosphate binder. In this review, we will examine these issues and provide rational guidelines for the use of calcium-based phosphate binders. Results from the calcium acetate Renagel evaluation study indicate that calcium acetate is more effective than sevelamer in controlling serum phosphorus and calcium x phosphorus product in hemodialysis patients. However, in the Treat-to-Goal study dialysis patients treated with sevelamer had less progression of coronary and aortic calcification than patients treated with calcium-containing binders. The mechanism underlying the slower rate of progression of cardiovascular calcification in sevelamer-treated patients remains uncertain but may relate to decreased calcium loading or to dramatic reductions in LDL cholesterol. At present, evidence incriminating calcium-containing phosphate binders in the progression of cardiovascular calcification in end-stage renal disease remains largely circumstantial. As calcium acetate is more efficacious and cost-effective than sevelamer, it remains an accepted first-line drug. Treatment with sevelamer hydrochloride should be considered for patients with persistent hypercalcemia during calcium-based binder therapy despite appropriate adjustment of vitamin D therapy.Keywords
This publication has 25 references indexed in Scilit:
- Mechanisms of secondary hyperparathyroidismAmerican Journal of Physiology-Renal Physiology, 2002
- Pathogenesis of parathyroid dysfunction in end-stage renal disease.Advances in Renal Replacement Therapy, 2002
- Cardiovascular calcification in end‐stage renal diseaseNephrology Dialysis Transplantation, 2002
- Association of Elevated Serum PO4, Ca × PO4 Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis PatientsJournal of the American Society of Nephrology, 2001
- Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patientsCurrent Opinion in Nephrology and Hypertension, 2001
- Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in managementAmerican Journal of Kidney Diseases, 2000
- Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing DialysisNew England Journal of Medicine, 2000
- Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national studyAmerican Journal of Kidney Diseases, 1998
- Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failureAmerican Journal of Kidney Diseases, 1997
- Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patientsAmerican Journal of Kidney Diseases, 1996